⚕ GalenOps CRO console
← SITE015 (POL)

SITE015-0443

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE015 (POL) (Dr. Ito) · consented 2023-09-08
Adverse events
9
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-09-28 (study day 7); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-10-03 (study day 12); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-10-20 (study day 29); relationship: N

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-13 (study day 53); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-12-04 (study day 74); relationship: not assessed

severe serious assessed 2026-08-18

Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-12-04 (study day 74); relationship: Y; serious criteria: life-threatening

mild assessed 2026-08-18

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-12-10 (study day 80); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-12 (study day 113); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-24 (study day 125); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.